Phosphoglycerate kinase (PGK) catalyzes an important ATP-generating step in glycolysis. PGK1 deficiency is an uncommon X-linked inherited disorder, generally characterized by various combinations of non-spherocytic hemolytic anemia, neurological dysfunctions, and myopathies. Patients rarely exhibit all three clinical features. To provide a molecular framework to the different pathological manifestations, all known mutations were reviewed and 16 mutant enzymes, obtained as recombinant forms, were functionally and structurally characterized. Most mutations heavily affect thermal stability and to a different extent catalytic efficiency, in line with the remarkably low PGK activity clinically observed in the patients. Mutations grossly impairing protein stability, but moderately affecting kinetic properties (p.I47N, p.L89P, p.C316R, p.S320N, and p.A354P) present the most homogeneous correlation with the clinical phenotype. Patients carrying these mutations display hemolytic anemia and neurological disorders, and,except for p.A354P variant, no myopaty. Variants highly perturbed in both catalytic efficiency (p.G158V, p.D164V, p.K191del, D285V, p.D315N, and p.T378P) and heat stability (all, but p.T378P) result to be mainly associated with myopathy alone. Finally, mutations faintly affecting molecular properties (p.R206P, p.E252A, p.I253T, p.V266M, and p.D268N) correlate with a wide spectrum of clinical symptoms. These are the first studies that correlate the clinical symptoms with the molecular properties of the mutant enzymes. All findings indicate that the different clinical manifestations associated with PGK1 deficiency chiefly depend on the distinctive type of perturbations caused by mutations in the PGK1 gene, highlighting the need for determination of the molecular properties of PGK variants to assist in prognosis and genetic counseling. However, the clinical symptoms can not be understood only on the bases of molecular properties of the mutant enzyme. Different (environmental, metabolic, genetic and/or epigenetic) intervening factors can contribute toward the expression of PGK deficient clinical phenotypes.
Citation: Chiarelli LR, Morera SM, Bianchi P, Fermo E, Zanella A, Galizzi A, et al. (2012) Molecular Insights on Pathogenic Effects of Mutations Causing Phosphoglycerate Kinase Deficiency. PLoS ONE 7(2): e32065. doi:10.1371/journal.pone.0032065
Editor: Fernando Rodrigues-Lima, University Paris Diderot-Paris 7, France
Received: September 6, 2011; Accepted: January 22, 2012; Published: February 14, 2012
Copyright: © 2012 Chiarelli et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by grants from the University of Pavia “Fondi per la Ricerca di Ateneo.” The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Phosphoglycerate kinase (PGK) deficiency (OMIM 300653) is one of the relatively uncommon causes of hereditary non-spherocytic hemolytic anemia (HNSHA) which has gained the attention of physicians of different fields because a defective enzyme activity may also cause rhabdomyolysis, mental retardation, and various neurological disorders . PGK (EC 126.96.36.199) is an essential enzyme for all living organisms. It catalyzes the reversible phosphotransfer reaction from 1,3-bisphosphoglycerate (1,3-BPG) to MgADP to produce 3-phosphoglycerate (3-PG) and MgATP, an important ATP-generating step in glycolysis. In addition to its physiological activity, human PGK can phosphorylate L-nucleoside analogues, which are used in antiviral and anticancer therapies –. Moreover, PGK was also shown to participate in the DNA replication and repair in mammal cell nuclei . Finally, extracellular PGK has been recently reported to exhibit thiol reductase activity on plasmin, leading to angiostatin formation, which inhibits angiogenesis and tumor growth , .
PGK is a typical hinge-bending monomeric enzyme containing two nearly equal-sized domains that essentially correspond to the N- and C-terminal portion of the protein . The N-terminal domain binds 3-PG or 1,3-BPG, whereas the C-terminal domain binds MgADP or MgATP. The two domains are separated by a deep cleft and linked by two alpha-helices (α-helix 7 and α-helix 14) , .
During the catalytic cycle the enzyme undergoes large conformational rearrangements, proceeding from an open form waiting for the substrates to a closed form performing the transfer of the phosphoryl group. Although conformational changes are promoted by substrate binding, only the concerted action of both substrates is able to trigger the domain closure, which leads to the proper geometry of the active site. Four hinge points contribute to the interdomain motions. Upon binding of the ligands the bending becomes restrained to a single hinge dominant point .
PGK requires magnesium ions for its activity and is characterized by an unusual kinetic behavior toward both substrates, being activated at high concentrations of either 3-PG or MgATP . Thus, the kinetic profiles of PGK do not obey a simple Michaelis-Menten model and Lineweaver-Burk plots are biphasic. The enzyme is also activated by low concentrations of various multivalent anions, such as pyrophosphate, sulfate, phosphate, citrate. The anion activation, which is displayed at low substrate concentrations, seems to make the Lineweaver-Burk plots linear toward substrates . The rationale of the kinetic behavior of PGK has not been so far unraveled, although basing on crystallographic studies an enzyme model has been suggested in which a secondary regulatory site is formed upon domain closure, in addition to the primary catalytic site . Thus, at low concentrations the anion can bind to the regulatory site and increases PGK activity, whereas at high concentrations the anion can substitute the substrate at the catalytic site and therefore acquires inhibitory functions .
Two human phosphoglycerate kinase isoenzymes, PGK1 and PGK2, have been so far identified, characterized by distinctive tissue localization and encoded by two distinct genes , . PGK1 is ubiquitously expressed in all somatic cells, including the red blood cells (RBC). Its gene maps to chromosome Xq13.3, spans approximately 23 kilobases and contains 11 exons and 10 introns . PGK2, also known as testis form, is unique to meiotic/postmeiotic spermatogenic cells, and is expressed by an intronless gene which maps to chromosome 6p12–21.1 , . The PGK2 gene is a retroposon which arose by reverse transcriptase-mediated processing of a transcript from PGK1 gene. In the human genome two non-functional pseudogenes have also been detected both presumably derived from the PGK1 gene and mapping to chromosome Xq12 and 19p13, respectively .
PGK1 and PGK2 isoenzymes are structurally and functionally similar. They are both 417 amino acid-long with 87–88% amino acid sequence identity, and an apparent molecular mass of approximately 45 kDa.
PGK1 deficiency is inherited as an X-linked recessive trait. Thus, males have full expression of the disorder, whereas females are usually asymptomatic sharing a population of deficient cells coexisting with a normal cell population. Since the first description by Kraus et al. , nearly 40 patients with PGK1 deficiency have been reported, 27 of them characterized at molecular level.
Twenty different mutations have been so far identified (Table 1) –. Fifteen are missense mutations, two deletions of the coding region and three alterations of the splicing site. PGK1 deficiency is generally associated with moderate to severe non-spherocytic hemolytic anemia, often accompanied with central nervous system (CNS) disorders. In some cases PGK deficient patients exhibit muscular disorders. Mental retardation, behavioral abnormalities, seizures or strokes represent the main neurological alterations, whereas cramps and myoglobinuria characterize the myopathic forms. Interestingly, patients generally exhibit myopathy only after prolonged physical exercise. The reasons for the phenotypic variability associated with mutations of the PGK1 gene are still unknown and worthy unraveling.
In this study, the properties of 16 mutant enzymes obtained as recombinant forms were investigated and compared to those of the recombinant wild-type enzyme with the final aim to define the properties of the protein, and to correlate them with the pathological outcome.
Materials and Methods
Restriction enzymes and Taq polymerase were purchased from New England Biolabs. AMV reverse transciptase from Roche Diagnostics. Oligonucleotides were synthesized by Invitrogen. Quick Change XL Site-Directed Mutagenesis Kit was from Stratagene. ATP, 3-phosphoglycerate (3-PG), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), NADH, isopropyl-β-D-thiogalactopyranoside (IPTG) were from Sigma-Aldrich. Other chemicals were reagent grade.
Construction of expression vector encoding PGK1
To obtain the nucleotide sequence encoding PGK1, peripheral blood (10 ml) was collected from a normal subject after obtaining written informed consent and approval from the Institutional Human Research Committee of Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico of Milano. After blood collection, subject's name was replaced with codes to ensure anonymity. The procedures followed were in accordance with the Helsinki International ethical standards on human experimentation. Total RNA, obtained from leucocytes by Trizol method  was reverse transcribed, and the entire cDNA was amplified by polymerase chain reaction (PCR, 94°C, 30 sec; 58°C, 30 sec; 72°C, 120 sec; 35 cycles), using primers designed according to the reference sequence (NCBI Reference Sequence: NM_000291.3). The forward primer was 5′-TCGTTGACCGAATCACCGAC; the reverse primer was 5′-GTGCATTCTAGAGTGCATATATTT. The product was cloned into pCRII-TOPO vector (TA Cloning Kit; Invitrogen) and sequenced. A transition A>G was inadvertently generated at nucleotide 117 after the stop codon.
The insert of the recombinant pCRII-TOPO vector was PCR amplified (94°C, 20 sec; 52°C, 30 sec; 72°C, 90 sec; 5 cycles; 94°C, 20 sec; 60°C, 30 sec; 72°C, 90 sec; 25 cycles) using 5′-CCGTCTTCATATGTCGCTTTCTAACAAGCTGAC as forward primer, and 5′-CCGCTGGAGCTATTAAATATTGCTGAGAGCATCCACC as reverse primer, which included NdeI and XhoI sites, respectively. After digestion, the PGK1 cDNA was inserted into NdeI/XhoI sites of pET-23b(+) expression vector (Novagen). The recombinant expression vector obtained was designed pMM1. The insert was checked by sequencing.
Construction of expression vectors encoding mutant PGK1 enzymes
To obtain mutant enzymes, pMM1 was subjected to site-directed mutagenesis using Quick Change XL Site-directed Mutagenesis Kit (Stratagene) and sense and antisense mutagenic oligonucleotides. In all cases, but two, the oligonucleotides contained a single mutated base at the middle of their sequence. In the case of p.V266M, the oligonucleotides contained two mutated bases, whereas in the case of p.K191del, the oligonucleotides were without the codon for lysine (Table 2). The presence of the desired mutations and the absence of unwanted additional mutations were confirmed by sequencing the inserts.
Expression and purification of PGKI enzymatic forms
Wild-type and mutant enzymes were expressed in E.coli BL21(DE3) pLysS cells transformed with the selected plasmids after a 5-hours induction with 0.5 mM isopropyl-β-D-thiogalactopyranoside. The induction temperature was 37°C for the following enzymes: wild-type, p.R206P, p.E252A, p.I253T, p.V266M, p.D268N. To express the remaining enzymes the induction temperature was lowered to 25°C.
To purify the enzymes, cells from one liter culture were collected by centrifugation, suspended in 50 ml Buffer A (20 mM Tris(tris(hydroxymethil)aminomethane)-HCl pH 8.0, 1 mM EDTA, 2 mM β-mercaptoethanol), sonicated, centrifuged and the supernatant, after an additional centrifugation at 150.000 g, was applied to a 27×4 cm DEAE-Sepharose FF (GE Healthcare) column equilibrated in buffer A. The enzyme activity was eluted as a sharp single peak using equilibration buffer. The enzyme obtained from one liter culture was approximately 90 mg in the case of the wild-type recombinant form. Mutant enzymes were generally expressed at lower level (Table 3). Protein quantification was determined according to Lowry et al. .
Molecular mass determination
To determine the molecular mass of the native enzyme, the purified PGK1 (100 µl, 0.1 mg/ml) was subjected to an analytical gel filtration on a Superose 12 HR 10/30 pre-packed column (GE-Healthcare) equilibrated in buffer A. For column calibration the following proteins were used: aldolase (120 kDa), albumin (67 kDa), ovoalbumin (45 kDa), chimotrysinogen (25 kDa) and ribonuclease (14 kDa).
Enzyme activity assay
The enzyme activity of PGK1 was determined at 37°C, with 3-PG and MgATP as substrates, by GAPDH coupled spectrophometric assay according to the method recommended by the International Committee for Standardization in Hematology . The standard reaction mixture contained 100 mM Tris pH 8.0, 0.5 mM EDTA, 2 mM MgCl2, 0.24 mM NADH, 40 µg GAPDH, 5 mM 3-PG, and 5 mM MgATP, in a final volume of 0.5 ml. The reaction was started by adding enzyme solution (0.1–0.5 µg). One unit is the amount of enzyme catalyzing the oxidation of 1 µmol NADH/min under the above conditions.
Enzyme kinetic studies
Enzymatic activity was assayed at 37°C by using various concentrations of 3-PG and MgATP under conditions identical to those described above except for substrates. Kinetic parameters were determined as follows: for 3-PG at fixed concentration of 5 mM MgATP; for MgATP at fixed concentration of 5 mM 3-PG. In all cases the reaction was started by adding the enzyme (0.1–0.8 U/ml) and the enzyme activity was assayed at least at 10 different concentrations of substrate. All measurements were performed in triplicate by using a Jasco V-550 UV/VIS spectrophotometer (Jasco-Europe).
Kinetic parameters were calculated according to Szilagyi et al. , and using the Sigma Plot software (SPSS Inc).
kcat, or turnover number, is the number of catalytic events per second. Km is the substrate concentration at which the reaction velocity is half maximal. kcat/Km is a measure of how efficiently an enzyme converts substrate to product at subsaturating substrate concentrations.
Thermal stability assays
The thermal stability was measured by incubating the enzyme (0.1–0.2 mg/ml) at given temperatures in buffer A. At intervals, samples were removed, chilled and assayed for enzyme activity. Relative activity was calculated as the percent of the enzyme activity before the incubation; t1/2 is the time required by the enzyme to lose 50% of its activity at a given temperature; T50 is the temperature at which the enzyme loses 50% of its activity in 10 min.
To study the effects of genetic mutations on the molecular properties of PGK1, the desired modifications (Table 1) were introduced into the cloned cDNA of PGK1 gene, and the mutated enzymatic forms were expressed in a bacterial system, purified to homogeneity and biochemically characterized. Maximal expression of most enzymes was obtained at 25°C (Table 3). The three-dimensional structure of the enzyme showing the amino acid residues affected by the mutations is represented in Figure 1. The adopted amino acid numbering is referred to the protein form which includes the initial methionine. Based on both 12% SDS-PAGE and analytical gel filtration chromatography, all enzymes examined were monomers of approximately 45 kDa (Figure 2).
Three-dimensional structure of open (A) and closed (B) human PGK1. The figures were generated from the atomic coordinates of Protein Data Bank, entry 2XE7 and 2WZC, using the Swiss-Pdb viewer (http://expasy.org/spdbv/). The black spheres indicate the Cα atoms of the amino acid residues subjected to mutagenesis. The arrows point to the substrates binding sites.
Elution profile of PGK1 from the analytical gel-filtration on a Superose 12HR 10/30 prepacked column. The position of the peak corresponds to a protein of approximately 45 kDa. The inset shows 12% SDS-PAGE of the purified PGK1 run in parallel with molecular mass standards, and stained with Coomassie Blue R-250.
Protein thermal stability
Thermal stability was evaluated both in wild type and mutant PGK1 enzymes. All enzymes were initially treated at 45°C (the temperature commonly used in clinical analysis of PGK1 deficiency, Figure 3,A) and their half-life values (t1/2, see Material and Methods) were calculated (Table 4). The wild-type form was stable, retaining full activity after two hours of incubation at this temperature. One group of 5 mutant enzymes (p.E252A, p.I253T, p.V266M, p.D268N and p.T378P) had at 45°C a behavior similar to that of the wild-type enzyme (t1/2 values, >60 min) and, except for p.R206P, the remaining enzymes were highly sensitive to heat, halving their respective activities in less than 8 minute-incubation at 45°C. p.I47N, p.L89P, p.D164V, p.D285V, p.D315N, p.C316R, p.S320N and p.A354P showed the highest instability, their activities dropping to 50% after less than 30 minutes of incubation at the physiological temperature of 37°C (Figure 3,B).
Thermal stability of the PGK1 wild-type and variants at 45°C (panel A) and at 37°C (panel B). Each enzyme was incubated in buffer A and aliquots were collected at intervals for measuring residual activity. Plot of the residual activities at 10 minutes versus temperatures (panel C). Each enzyme was subjected to heat inactivation in a range of temperature from 25°C to 60°C. After 10 minutes of incubation at a given temperature, the enzyme sample was chilled and the residual activity measured. Residual activity was expressed as percentage of initial activity. •, wild-type; ▪, p.I47N; ▴, p.L89P; ▾, p.G158V; ⧫ p.D164V; , p.K191del; ○, p.R206P; □, p.E252A; ▵, p.I253T; ▿, p.V266M; ⋄, p.D268N; , p.D285V; , p.D315N; , p.C316R; , p.S320N; , p.A354P; , p.T378P.
Moreover, an additional and more in-depth thermal analysis was performed incubating the enzymes at a wider range of temperatures (25°C–60°C; Figure 3,C), and calculating the temperatures at which they lost 50% of their respective activities after a period of ten minutes (T50). T50 was 49°C for the wild-type PGK1. Only 5 mutant enzymes (p.E252A, p.I253T, p.V266M, p.D268N, and p.T378P) had values comparable or even higher than that of the wild-type, all other variants tested had T50 values lower than the control. In some instances the T50 was reduced of more than 10°C (Table 4).
Kinetic analysis of the wild-type PGK1 and mutant enzymes
The residual enzymatic activities reported in the literature associated with PGK1 gene mutations are shown in Table 1. Enzyme activity is generally lower than 10% of normal, except for p.D268N, p.D285V and p.S320N variants (21%, 49% and 36%, respectively).
In an attempt to understand the reason for the observed decreased activity, the kinetic properties of the wild-type and mutant enzymes were compared. Kinetic analyses were performed on the reverse reaction, at fixed concentration of free Mg2+ and using either MgATP (Figure 4,A) or 3-PG (Figure 4,B) as variable substrate. In all cases, the curve of velocity versus substrate concentration could not be fitted by a single hyperbola (non-Michaelian character), since the enzymes were activated by high concentrations of substrates. As a consequence the double reciprocal plots of the kinetic data were biphasic, represented by an interrupted straight line. For this reason the apparent Km and kcat values reported in Table 5 were obtained extrapolating the linear portion of the curves in the low substrate concentration range excluding the data affected by substrate activation. This range of substrate concentrations likely approaches the physiological situation.
Steady state kinetics of PGK1 wild-type and variants as a function of Mg-ATP at fixed 5 mM 3-PG (panel A) and as a function of 3-PG at fixed 5 mM MgATP (panel B). All experiments were performed at 37°C as reported in the "Material and Methods" section. •, wild-type; ▪, p.I47N; ▴, p.L89P; ▾, p.G158V; ⧫ p.D164V; , p.K191del; ○, p.R206P; □, p.E252A; ▵, p.I253T; ▿, p.V266M; ⋄, p.D268N; , p.D285V; , p.D315N; , p.C316R; , p.S320N; , p.A354P; , p.T378P.
As for kinetics versus MgATP (Figure 4,A), the apparent Km of the wild-type enzyme was valued at 0.28 mM, and the apparent kcat at 553 sec−1. All variants showed an affinity toward this substrate similar to that of the wild-type, with the exception of p.D315N and p.T378P. In both cases, the apparent Km value was five-fold higher than that of the wild-type enzyme (1.36 mM and 1.43 mM, respectively). For most mutants the catalytical rates were affected, although to a different extent. Outstanding are the apparent kcat values of variants p.G158V, p.D164V, p.D285V and p.T378P that were 10% or less than that of the wild-type enzyme.
When 3-PG was the variable substrate (Figure 4,B), the wild-type enzyme exhibited an apparent Km value equal to 0.17 mM and an apparent kcat value of 468 sec−1. pD164V and p.K191del showed a significant reduction of their affinity toward 3-PG (apparent Km, 1.07 mM and 1.52 mM, respectively), whereas all other variants behaved like the wild-type enzyme. As far as the apparent kcat was concerned, as in the case of MgATP, p.G158V, p.D164V, p.D285V and p.T378P showed values lowered to 10% that of wild-type enzyme.
The main objective of this research was to define how the enzyme alterations caused by PGK1 mutations could affect enzyme activity and generate the clinical manifestations of this disease. To this purpose, all the 20 mutations so far reported in literature were reviewed (Table 1) and 16 of them investigated at the protein level using purified preparations of the enzymes (Tables 4 and 5). The remaining four mutations were not considered, being predicted to have dramatic outcomes, such as complete absence of the protein product or an aberrant form of it.
The in-depth biochemical characterization of PGK1 variants shows that all mutations, with few exceptions, heavily impair the thermal stability and, to a different extent, the catalytic properties of the enzymes (Tables 4 and 5). Thus, the severity of molecular defects generally accounts for the remarkably low (mostly, <10% of normal) PGK activity observed in patients (Table 1).
A possible correlation with the different clinical manifestations of PGK deficient patients has been evidenced by grouping the characterized enzymatic variants according to their molecular defects (Table 6). The molecular interactions potentially affected by mutations, as inferred by the three-dimensional structures of human PGK1 in the open and in the closed form , , are shown in Table 7.
One group of 5 mutant enzymes including p.I47N (Barcelona), p.L89P (Matsue), p.C316R (Michigan), p.S320N (Murcia), and p.A354P (Kyoto), are grossly perturbed in their protein stability and moderately affected in kinetic properties. A common clinical phenotype can be observed in patients carrying these mutations: all of them in fact display chronic hemolytic anemia and neurological dysfunctions, and except for p.A354P, no myopathy.
A second group of 6 variants comprising p.G158V (Shizuoka), p.D164V (New York/Amiens), p.K191del (Alabama), p.D285V (Herlev), p.D315N (Creteil), and p.T378P (Afula) display a great reduction of catalytic efficiency, mostly due to a cut of catalytic rate (kcat), and in some cases (p.D164V, p.K191del, p.D315N, and p.T378P) coupled with an increase of apparent Km values (Table 5). Moreover, with the exception of p.T378P, all members of this group are highly heat sensitive, suggesting that the carriers of these mutations should suffer from a multisystem disease (erythrocyte, muscle, and CNS involvement). Intriguingly, with the exception of the carriers of p.D164V, all the other patients show neither chronic hemolytic anemia nor neurological dysfunctions. Three of them have myopathy.
Lastly, a group of 5 variants, namely p.R206P (Uppsala), p.E252A (Antwerp), p.I253T (Hamamatsu), p.V266M (Tokio), and p.D268N (Munchen) do not display heavy alterations of their molecular properties, on the whole behaving like the wild-type enzyme. The patients differ one from each other for clinical symptoms.
A more detailed discussion of each group follows.
The first group of mutations stands out from the others since it presents the most homogeneous correlation with tissues affected (erythrocytes and CNS). In addition, all patients were diagnosed in childhood (Table 1). The mutations affect above all the amino acid residues which play a main role in preserving protein structure. For instance, I47 and L89 are involved on both hydrogen/ionic and hydrophobic interactions in both open and closed conformations (Table 7). In addition L89 is substituted by an α-helix-destabilizing proline inside the α-helix 2. In a similar way the instability of the variant A354P can find an explanation in the introduction of the proline in α-helix 12. Therefore, a possible explanation for the absence of muscular dysfunctions is that the skeletal muscle has the capability to promptly replace the enzyme fraction damaged by a sudden increase of body temperature (fever or strenuous exercise gives rise to physiological temperature increase ). The mutant enzymes, although thermolable, have enough activity to allow sufficient metabolic flow in glycolysis.
Mature RBC face a different situation, being prevented from performing protein synthesis. Thus, an increased degradation rate of such variants leads to a decreased PGK1 content which primarily accounts for the enzyme deficiency and in turn for a reduced ATP production. Anyway, in these conditions RBC could count on the Rapoport-Luebering shunt for energy generation bypassing the PGK1 reaction . Nevertheless, severe anemia is observed. It is conceivable, as previously suggested , that the true cause of the hemolysis is better ascribable to an increase of acidity or inhibition of several glycolytic enzymes (such as hexokinase, phosphofructo kinase, and pyruvate kinase) as a consequence of an increased intracellular concentration of 2,3-BPG, as already reported , , , , , .
As for the neurological dysfunctions, the tissue presumably does not promptly supply new enzyme to replace the damaged fraction, leading to a depletion of ATP. Moreover, the reduced production of 3-PG could affect the biosynthesis of some derived neuromodulators .
With the mutants of the second group, in which all amino acids affected by mutations are involved in hydrogen/ionic interactions (Table 7), we are faced by a tangled situation in which the occurrence of quite obscure factors has to be invoked from time to time to explain the reasons of the different clinical signs of patients. The carriers of p.G158V p.D315N and p.T378P are all characterized by muscle weakness and myoglobinuria after induced exercise, without chronic anemia and CNS dysfunction , , . The present data highlight the deleterious effects of mutations on the enzyme (p.G158V, catalytic activity reduced to approximately 8%, T50, 6.5°C lowered; p.D315N and p.T378P, catalytic efficiency reduced to 5% and 1.5%, respectively, mainly as a consequence of lowered affinity toward Mg-ATP; T50 reduced by 9°C, only in the case of p.D315N). Peculiar is the behavior of the enzyme isolated from the RBC of patient with p.G158V substitution, that has characteristics similar to the wild-type . A possible explanation is that the enzyme isolated from RBC is the ectopically expressed PGK2 isoenzyme. An ectopic expression of PGK2 can probably occur in those tissues where the activity of PGK1 is absent. This suggestion is supported by the fact that mutations leading to aberrant forms of PGK1 (the last 4 mutations in Table 1) are associated with a clinical phenotype similar to that of the carriers of p.G158V, p.D315N and p.T378P. The uncontrolled expression of PGK2 or epigenetic events have been already called into question to explain the mild phenotype associated to the in-frame deletion delAAG c.571>573 or delAAG c.574>576, which result in a PGK1 protein lacking one of the tandem lysine residues at position 191 or 192 of the polypeptide chain . This mutation has been detected in a patient 36-year old, affected by PGK1 deficiency with episodes of hemolysis with jaundice, mainly in correspondence of febrile episodes . The present data show that both lysine residues of this region are fundamental not only for preserving protein stability, as previously suggested , but most of all for ensuring 3-PG binding and catalytic function (Table 5). K191 and K192 are part of α-helix 7, a crucial region of the enzyme between the N-terminal and C-terminal domain. Deletion of one lysine is likely to shift the arrangement of the amino acid residues, affecting key interactions responsible for domain-domain communications and, although indirectly, for 3-PG binding (L189 with D164; E193 with H391, S393 and T394 of the hinge βL; F197 with F166 of α-helix 5 in the vicinity of 3-PG binding site) . Mutation p.K191del should be deleterious for all tissues that primarily use glycolytic pathway to obtain ATP. Therefore, these tissues have to rely on the alternative PGK2 activity.
The carrier of p.D285V  was reported to be in good health along his life and the diagnosis of PGK1 deficiency was performed when he was elderly. Curiously, his RBC residual activity is 49% of normal, in strong contradiction with the serious enzyme alterations evidenced in this study. Conceivably, the p.D285V substitution abolishes the hydrogen interactions established by D285 with the backbone of G317, E319 and S320 in α-helix 11 (Table 7), thus affecting a H-bonding network essential for the molecule arrangement . Noteworthy, the nucleotide substitution (c.854 A>T) was only observed in about 90% of the DNA studied and different hypotheses have been proposed to solve this riddle. The present data reinforce the suggestion that this mutation in the PGK1 gene occurred postzygotically, with only a fraction of the cells in the soma carrying the mutation , thus leaving the carrier asymptomatic.
c.491 A>T mutation turns out to be the most deleterious at the protein level. In fact, p.D164V variant has a nearly 20-fold reduction in its catalytic rate toward both substrates and a six-fold reduction in its affinity for 3-PG, which is reflected in a substantial decrease in the catalytic efficiency toward this substrate (2-order of magnitude lower than that of wild-type). Moreover, the mutant enzyme is severely affected in its protein stability (t1/2 at 37°C, 11 min). Most probably, D164 is functionally important in both 3-PG binding, although indirectly, and in transmitting to C-domain the conformational changes induced by 3-PG binding. Besides, the molecular interactions engaged by D164 with its counterparts are crucial for preserving the native structure of the enzyme. D164 is located at the terminus of β-E strand in N-domain and interacts with the backbone of residues located at position 188, 189 and 190 of α-helix 7 of PGK1 (Table 7). c.491 A>T is the most frequent mutation affecting the PGK1 gene, being found in 7 patients belonging to four different families –. All these patients have chronic hemolytic anemia and neurological dysfunctions, but no signs of muscular disorders.
With regard to the third group of mutations, data suggest that clinical manifestations of these patients are not the consequence of the amino acid substitutions in PGK1, the variants displaying features of the authentic enzyme, at least at physiological conditions.
p.D268N variant, described in a population survey , is associated with an asymptomatic clinical phenotype. The erythrocyte residual activity is 20% of normal (Table 1). Thus, as previously reported , the decreased enzyme activity, at least in the RBC, could be due to a decreased protein content ensuing from the nucleotide substitution.
The mutation causing p.E252A substitution is a nucleotide transversion (A>C) at nt 755 position of PGK1 c.DNA, just adjacent to the 3′ end of exon 7. As a consequence, the consensus 5′ splicing sequence AGgt is changed to a nonconsensus sequence CGgt leading to a reduction of splicing efficiency (approximately only 10%) . Thus, the highly reduced activity found in cells (8% in muscle, 6% in RBC) is most likely a result of a low content of PGK1, due to a reduced maturation of its mRNA. Thus, not surprisingly, the clinical phenotype (myophaty, but no anemia or neurological defects) is similar to that shown by the patients with other splicing mutations (Table 1).
The clinical manifestations associated to p.I253T, p.V266M and p.R206P mutations (recurrent myoglobinuria and mental retardation, but no hemolysis, in the first case ; hemolysis and neurological signs but no myopaty, in the second case ; mild hemolytic anemia and mental retardation, but no rabdomyolysis in the third case , ) can not be understood only on the bases of well-defined molecular properties of the mutant enzyme.
In conclusion, the hemolytic disorder associated with neurological dysfunctions is in general present in PGK deficient patients with variants unstable but only mildly affected in catalytic properties. Conversely, the myopathy without hemolytic or neurological symptoms is observed in some patients with variants heavily affected in both catalytic properties and protein stability (Table 6). Thus, different clinical phenotypes correlate with the distinctive type of perturbations caused by the mutations, stressing the need for the determination of the molecular properties of PGK variants to assist in prognosis and genetic counseling.
The occurrence of additional genetic and/or epigenetic factors that contribute to the phenotypic variability cannot be excluded. The ectopic expression of an isoenzyme has been already described, for instance, in the case of pyruvate kinase deficiency . Pharmacological, nutritional and, more in general, environmental factors cannot be dismissed, especially in consideration of the paucity of reported cases of PGK1 deficiency. The secondary activities described for the enzyme, such as thiol reductase, replication and repair of DNA, may as well be responsible of some clinical manifestations.
Conceived and designed the experiments: GV LRC. Performed the experiments: EF LRC PB SMM. Analyzed the data: AG AZ GV LRC PB SMM. Wrote the paper: AG GV.
- 1. Beutler E (2007) PGK deficiency. Br J Haematol 136: 3–11.
- 2. Krishnan P, Gullen EA, Lam W, Dutschman GE, Grill SP, et al. (2003) Novel role of 3-phosphoglycerate kinase, a glycolytic enzyme, in the activation of L-nucleoside analogs, a new class of anticancer and antiviral agents. J Biol Chem 278: 36726–36732.
- 3. Gallois-Montbrun S, Faraj A, Seclaman E, Sommadossi JP, Deville-Bonne D, et al. (2004) Broad specificity of human phosphoglycerate kinase for antiviral nucleoside analogs. Biochem Pharmacol 68: 1749–1756.
- 4. Gondeau C, Chaloin L, Lallemand P, Roy B, Périgaud C, et al. (2008) Molecular basis for the lack of enantioselectivity of human 3-phosphoglycerate kinase. Nucleic Acids Res 36: 3620–3629.
- 5. Jindal HK, Vishwanatha JK (1990) Functional identity of a primer recognition protein as phosphoglycerate kinase. J Biol Chem 265: 6540–6543.
- 6. Lay AJ, Jiang XM, Kisker O, Flynn E, Underwood A, et al. (2000) Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature 408: 869–873.
- 7. Shichijo S, Azuma K, Komatsu N, Ito M, Maeda Y, et al. (2004) Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer. Clin Cancer Res 10: 5828–5836.
- 8. Vas M, Varga A, Gráczer E (2010) Insight into the mechanism of domain movements and their role in enzyme function: example of 3-phosphoglycerate kinase. Curr Protein Pept Sci 11: 118–147.
- 9. Palmai Z, Chaloin L, Lionne C, Fidy J, Perahia D, et al. (2009) Substrate binding modifies the hinge bending characteristics of human 3-phosphoglycerate kinase: a molecular dynamics study. Proteins 77: 319–329.
- 10. Larsson-Raźnikiewicz M (1967) Kinetic studies on the reaction catalyzed by phosphoglycerate kinase. II. The kinetic relationships between 3-phosphoglycerate, MgATP2-and activating metal ion. Biochim Biophys Acta 132: 33–40.
- 11. Scopes RK (1978) The steady-state kinetics of yeast phosphoglycerate kinase. Anomalous kinetic plots and the effects of salts on activity. Eur J Biochem 85: 503–516.
- 12. Szilágyi AN, Vas M (1998) Anion activation of 3-phosphoglycerate kinase requires domain closure. Biochemistry 37: 8551–8563.
- 13. Willard HF, Goss SJ, Holmes MT, Munroe DL (1985) Regional localization of the phosphoglycerate kinase gene and pseudogene on the human X chromosome and assignment of a related DNA sequence to chromosome 19. Hum Genet 71: 138–143.
- 14. McCarrey JR, Thomas K (1987) Human testis-specific PGK gene lacks introns and possesses characteristics of a processed gene. Nature 326: 501–505.
- 15. Michelson AM, Blake CC, Evans ST, Orkin SH (1985) Structure of the human phosphoglycerate kinase gene and the intron-mediated evolution and dispersal of the nucleotide-binding domain. Proc Natl Acad Sci U S A 82: 6965–6969.
- 16. Kraus AP, Langston MF Jr, Lynch BL (1968) Red cell phosphoglycerate kinase deficiency. A new cause of non-spherocytic hemolytic anemia. Biochem Biophys Res Commun 30: 173–177.
- 17. Noel N, Flanagan JM, Ramirez Bajo MJ, Kalko SG, Mañú M del M, et al. (2006) Two new phosphoglycerate kinase mutations associated with chronic haemolytic anaemia and neurological dysfunction in two patients from Spain. Br J Haematol 132: 523–529.
- 18. Maeda M, Yoshida A (1991) Molecular defect of a phosphoglycerate kinase variant (PGK-Matsue) associated with hemolytic anemia: Leu>Pro substitution caused by T/A>C/G transition in exon 3. Blood 77: 1348–1352.
- 19. Fujii H, Kanno H, Hirono A, Shiomura T, Miwa S (1992) A single amino acid substitution (157 Gly>Val) in a phosphoglycerate kinase variant (PGK Shizuoka) associated with chronic hemolysis and myoglobinuria. Blood 79: 1582–1585.
- 20. Cohen-Solal M, Valentin C, Plassa F, Guillemin G, Danze F, et al. (1994) Identification of new mutations in two phosphoglycerate kinase (PGK) variants expressing different clinical syndromes: PGK Créteil and PGK Amiens. Blood 84: 898–903.
- 21. Turner G, Fletcher J, Elber J, Yanagawa Y, Davé V, et al. (1995) Molecular defect of a phosphoglycerate kinase variant associated with haemolytic anaemia and neurological disorders in a large kindred. Br J Haematol 91: 60–65.
- 22. Flanagan JM, Rhodes M, Wilson M, Beutler E (2006) The identification of a recurrent phosphoglycerate kinase mutation associated with chronic haemolytic anaemia and neurological dysfunction in a family from USA. Br J Haematol 134: 233–237.
- 23. Rhodes M, Ashford L, Manes B, Calder C, Domm J, et al. (2011) Bone marrow transplantation in phosphoglycerate kinase (PGK) deficiency. Br J Haematol 152: 500–502.
- 24. Yoshida A, Twele TW, Davé V, Beutler E (1995) Molecular abnormality of a phosphoglycerate kinase variant (PGK-Alabama). Blood Cells Mol Dis 21: 179–181.
- 25. Hjelm M, Wadam B, Yoshida A (1980) A phosphoglycerate kinase variant, PGK Uppsala, associated with hemolytic anemia. J Lab Clin Med 96: 1015–1021.
- 26. Fujii H, Yoshida A (1980) Molecular abnormality of phosphoglycerate kinase-Uppsala associated with chronic nonspherocytic hemolytic anemia. Proc Natl Acad Sci U S A 77: 5461–5465.
- 27. Ookawara T, Davé V, Willems P, Martin JJ, de Barsy T, et al. (1996) Retarded and aberrant splicings caused by single exon mutation in a phosphoglycerate kinase variant. Arch Biochem Biophys 327: 35–40.
- 28. Sugie H, Sugie Y, Ito M, Fukuda T (1998) A novel missense mutation (837T→C) in the phosphoglycerate kinase gene of a patient with a myopathic form of phosphoglycerate kinase deficiency. J Child Neurol 13: 95–97.
- 29. Fujii H, Chen SH, Akatsuka J, Miwa S, Yoshida A (1981) Use of cultured lymphoblastoid cells for the study of abnormal enzymes: molecular abnormality of a phosphoglycerate kinase variant associated with hemolytic anemia. Proc Natl Acad Sci U S A 78: 2587–2590.
- 30. Fujii H, Krietsch WK, Yoshida A (1980) A single amino acid substitution (Asp leads to Asn) in a phosphoglycerate kinase variant (PGK München) associated with enzyme deficiency. J Biol Chem 255: 6421–6423.
- 31. Valentin C, Birgens H, Craescu CT, Brødum-Nielsen K, Cohen-Solal M (1998) A phosphoglycerate kinase mutant (PGK Herlev; D285V) in a Danish patient with isolated chronic hemolytic anemia: mechanism of mutation and structure-function relationships. Hum Mutat 12: 280–287.
- 32. Maeda M, Bawle EV, Kulkarni R, Beutler E, Yoshida A (1992) Molecular abnormalities of a phosphoglycerate kinase variant generated by spontaneous mutation. Blood 79: 2759–2762.
- 33. Morimoto A, Ueda I, Hirashima Y, Sawai Y, Usuku T, et al. (2003) A novel missense mutation (1060G>C) in the phosphoglycerate kinase gene in a Japanese boy with chronic haemolytic anaemia, developmental delay and rhabdomyolysis. Br J Haematol 122: 1009–1013.
- 34. Spiegel R, Gomez EA, Akman HO, Krishna S, Horovitz Y, et al. (2009) Myopathic form of phosphoglycerate kinase (PGK) deficiency: a new case and pathogenic considerations. Neuromuscul Disord 19: 207–211.
- 35. Sotiriou E, Greene P, Krishna S, Hirano M, DiMauro S (2010) Myopathy and parkinsonism in phosphoglycerate kinase deficiency. Muscle Nerve 41: 707–710.
- 36. Tsujino S, Tonin P, Shanske S, Nohria V, Boustany RM, et al. (1994) A splice junction mutation in a new myopathic variant of phosphoglycerate kinase deficiency (PGK North Carolina). Ann Neurol 35: 349–353.
- 37. Hamano T, Mutoh T, Sugie H, Koga H, Kuriyama M (2000) Phosphoglycerate kinase deficiency: an adult myopathic form with a novel mutation. Neurology 54: 1188–1190.
- 38. Aasly J, van Diggelen OP, Boer AM, Brønstad G (2000) Phosphoglycerate kinase deficiency in two brothers with McArdle-like clinical symptoms. Eur J Neurol 7: 111–113.
- 39. Svaasand EK, Aasly J, Landsem VM, Klungland H (2007) Altered expression of PGK1 in a family with phosphoglycerate kinase deficiency. Muscle Nerve 36: 679–684.
- 40. Shirakawa K, Takahashi Y, Miyajima H (2006) Intronic mutation in the PGK1 gene may cause recurrent myoglobinuria by aberrant splicing. Neurology 66: 925–927.
- 41. Goossens M, Kan YW (1981) DNA analysis in the diagnosis of hemoglobin disorders. Methods Enzymol 76: 805–817.
- 42. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275.
- 43. Beutler E, Blume KG, Kaplan JC, Löhr GW, Ramot B, et al. (1977) International Committee for Standardization in Haematology: recommended methods for red-cell enzyme analysis. Br J Haematol 35: 331–340.
- 44. Zerrad L, Merli A, Schröder GF, Varga A, Gráczer É, et al. (2011) A spring-loaded release mechanism regulates domain movement and catalysis in phosphoglycerate kinase. J Biol Chem 286: 14040–14048.
- 45. Cliff MJ, Bowler MW, Varga A, Marston JP, Szabó J, et al. (2010) Transition state analogue structures of human phosphoglycerate kinase establish the importance of charge balance in catalysis. J Am Chem Soc 132: 6507–6516.
- 46. Krustrup P, Ferguson RA, Kjaer M, Bangsbo J (2003) ATP and heat production in human skeletal muscle during dynamic exercise: higher efficiency of anaerobic than aerobic ATP resynthesis. J Physiol 549: 255–269.
- 47. van Wijk R, van Solinge WW (2005) The energy-less red blood cell is lost: erythrocyte abnormalities of glycolysis. Blood 106: 4034–4042.
- 48. Ramírez-Bajo MJ, Repiso A, de la Ossa PP, Bañón-Maneus E, de Atauri P, et al. (2011) Enzymatic and metabolic characterization of the phosphoglycerate kinase deficiency associated with chronic hemolytic anemia caused by the PGK-Barcelona mutation. Blood Cells Mol Dis 46: 206–211.
- 49. Tabatabaie L, Klomp LW, Berger R, de Koning TJ (2010) L-serine synthesis in the central nervous system: a review on serine deficiency disorders. Mol Genet Metab 99: 256–262.
- 50. Svirklys LG, Lee CS, O'Sullivan WJ (1986) Phosphoglycerate kinase: studies on normal and a mutant human enzyme. J Inher Metab Dis 9: 374–387.
- 51. Krietsch WK, Eber SW, Haas B, Ruppelt W, Kuntz GWK (1980) Characterization of a phosphoglycerate kinase deficiency variants not associated with hemolytic anemia. Am J Hum Genet 32: 364–373.
- 52. Kugler W, Willaschek C, Holtz C, Ohlenbusch A, Laspe P, et al. (2000) Eight novel mutations and consequences on mRNA and protein level in pyruvate kinase-deficient patients with nonspherocytic hemolytic anemia. Hum Mutat 15: 261–272.